https://www.nasdaq.com/press-release/atea-pharmaceuticals-to-present-at-40th-annual-j.p.-morgan-healthcare-conference-2022
https://www.nasdaq.com/press-release/atea-pharmaceuticals-added-to-the-nasdaq-biotechnology-index-2021-12-17
https://www.nasdaq.com/press-release/atea-pharmaceuticals-introduces-new-strategic-clinical-development-program-for-at-527
https://www.nasdaq.com/press-release/atea-pharmaceuticals-to-present-at-the-4th-annual-evercore-isi-healthconx-conference
https://www.nasdaq.com/press-release/atea-pharmaceuticals-provides-update-on-strategic-collaboration-with-roche-2021-11-16
https://www.nasdaq.com/press-release/atea-pharmaceuticals-provides-clinical-and-corporate-update-and-reports-third-quarter
https://www.nasdaq.com/press-release/atea-pharmaceuticals-to-host-third-quarter-financial-results-conference-call-on
https://www.nasdaq.com/press-release/atea-pharmaceuticals-provides-update-and-topline-results-for-phase-2-moonsong-trial
https://www.nasdaq.com/press-release/atea-pharmaceuticals-to-present-virology-and-early-clinical-data-at-the-isirv-who
https://www.nasdaq.com/press-release/atea-pharmaceuticals-to-present-at-guggenheim-2nd-annual-vaccines-infectious-day
https://www.nasdaq.com/press-release/atea-pharmaceuticals-to-present-at-the-morgan-stanley-19th-annual-global-healthcare
https://www.nasdaq.com/press-release/atea-pharmaceuticals-announces-publication-of-data-highlighting-at-752s-potent-in
https://www.nasdaq.com/press-release/atea-pharmaceuticals-provides-clinical-and-corporate-update-and-reports-second
https://www.nasdaq.com/press-release/atea-pharmaceuticals-to-host-second-quarter-financial-results-conference-call-on
https://www.nasdaq.com/press-release/atea-pharmaceuticals-to-present-at-william-blair-biotech-focus-conference-2021-07-12
https://www.nasdaq.com/press-release/ateas-at-527-an-oral-antiviral-drug-candidate-reduces-viral-replication-in
https://www.nasdaq.com/press-release/atea-pharmaceuticals-announces-achievement-of-at-527-development-milestone-under
https://www.nasdaq.com/press-release/atea-pharmaceuticals-appoints-claudio-avila-mb-bs-ph.d.-as-senior-vice-president-of
https://www.nasdaq.com/press-release/atea-pharmaceuticals-to-present-at-jefferies-virtual-healthcare-conference-2021-05-26
https://www.nasdaq.com/press-release/atea-pharmaceuticals-appoints-jerome-adams-m.d.-m.p.h.-to-board-of-directors-2021-05
https://www.nasdaq.com/press-release/atea-pharmaceuticals-reports-first-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/atea-pharmaceuticals-to-host-first-quarter-financial-results-conference-call-on-may
https://www.nasdaq.com/press-release/atea-pharmaceuticals-announces-first-patient-dosed-in-global-phase-3-morningsky-trial
https://www.nasdaq.com/press-release/atea-pharmaceuticals-reports-full-year-2020-financial-results-and-provides-corporate
https://www.nasdaq.com/press-release/atea-pharmaceuticals-to-host-fourth-quarter-and-full-year-2020-financial-results
https://www.nasdaq.com/press-release/atea-pharmaceuticals-presents-favorable-phase-1-results-for-at-527-at-28th-annual
https://www.nasdaq.com/press-release/atea-pharmaceuticals-announces-chugai-in-license-of-at-527-from-roche-for-the
https://www.nasdaq.com/press-release/atea-pharmaceuticals-announces-publication-of-preclinical-data-highlighting-potent
https://www.nasdaq.com/press-release/atea-pharmaceuticals-announces-first-patient-dosed-in-phase-2-virology-trial-of-at
https://www.nasdaq.com/press-release/atea-pharmaceuticals-expands-senior-management-team-with-key-additions-in-regulatory
https://www.nasdaq.com/press-release/atea-pharmaceuticals-to-present-at-39th-annual-j.p.-morgan-healthcare-conference-2020
https://www.nasdaq.com/press-release/atea-pharmaceuticals-added-to-russell-2000-index-2020-12-18
